Anixa Biosciences Inc. Common Stock
Anixa Biosciences, Inc., a biotechnology company, develops therapies and vaccines focusing on critical unmet needs in oncology and infectious diseases. The company's therapeutics programs include the development of a chimeric endocrine receptor T-cell technology, a novel form of chimeric antigen receptor T-cell (CAR-T) technology focusing on the treatment of ovarian cancer; and the discovery and development of anti-viral drug candidates for the treatment of COVID-19 focused on inhibiting certain viral protein functions of the virus. Its vaccine programs comprise the development of a vaccine against triple negative breast cancer; and a vaccine against ovarian cancer. The company is also developing immuno-therapy drugs against cancer. It has a collaboration agreement with OntoChem GmbH to discover and develop anti-viral drug candidates against COVID-19. The company was formerly known as ITUS Corporation and changed its name to Anixa Biosciences, Inc. in October 2018. Anixa Biosciences, Inc. was founded in 1982 and is based in San Jose, California.
ANIX Overview
Sector |
Health Care |
Industry |
Major Pharmaceuticals |
Previous Close |
$3.7000 |
Previous Close Volume |
113540 |
Latest News
- Anixa Biosciences Board of Directors Approves Purchase of Bitcoin as Treasury Reserve Asset 22 Nov 2024 08:17:18
- Anixa Biosciences Initiates Dosing in Third Cohort in its Ovarian Cancer CAR-T Clinical Trial 18 Nov 2024 08:32:11
-
Anixa Biosciences to Present at the Sidoti Micro-Cap Virtual Conference on November 13 & 14, 2024
31 Oct 2024 08:15:50
https://ir.anixa.com/press-releases/detail/1056/anixa-biosciences-to-present-at-the-sidoti-micro-cap
-
Anixa Biosciences and Cleveland Clinic to Present Additional Data from Phase 1 Study of Breast Cancer Vaccine at the 39th Society for Immunotherapy of Cancer (SITC) Annual Meeting
28 Oct 2024 08:30:51
https://ir.anixa.com/press-releases/detail/1055/anixa-biosciences-and-cleveland-clinic-to-present
- Anixa Biosciences Announces Second Dose Administered to Patient in Ovarian Cancer CAR-T Clinical Trial 15 Oct 2024 09:02:23
-
Anixa Biosciences Announces Submission of Protocol Amendment for CAR-T Trial
30 Sep 2024 08:32:22
https://ir.anixa.com/press-releases/detail/1052/anixa-biosciences-announces-submission-of-protocol
- Anixa Biosciences Unveils Phase 2 Study Plan for Breast Cancer Vaccine 24 Sep 2024 08:30:53
- Anixa Biosciences to Present at the H.C. Wainwright 26th Annual Global Investment Conference 26 Aug 2024 08:32:04
- Anixa Biosciences Announces Presentation on its Ovarian Cancer CAR-T Clinical Trial at the International Gynecologic Cancer Society 2024 Annual Meeting 29 Jul 2024 08:47:21
- Anixa Biosciences Announces FDA Approval of Individual Patient IND for its Ovarian Cancer CAR-T Therapy 23 Jul 2024 08:17:22
- Anixa Biosciences Announces Japanese Patent on Breast Cancer Vaccine Technology 17 Jul 2024 08:02:24
- Anixa Biosciences Announces $5 Million Share Repurchase Program 15 Jul 2024 08:32:24
- Anixa Biosciences Treats Sixth Patient in its Ovarian Cancer CAR-T Clinical Trial 24 Jun 2024 08:47:22
- Anixa Biosciences Commences Treatment of Fifth Patient in Ovarian Cancer CAR-T Clinical Trial 21 May 2024 07:32:26
- Anixa Biosciences Expands Partnership with Cleveland Clinic to Develop Additional Cancer Vaccines 08 May 2024 08:32:25
- Anixa Biosciences CEO Featured on "Target: Cancer Podcast" by Oncologist Dr. Sanjay Juneja 06 May 2024 08:17:24
- Anixa Biosciences to Participate in the Sidoti Micro-Cap Virtual Conference on May 8 & 9, 2024 30 Apr 2024 07:47:25
- Anixa Biosciences Welcomes Celebrity Oncologist Dr. Sanjay Juneja to its Cancer Business Advisory Board 18 Apr 2024 08:32:30
- Anixa Biosciences 2024 Annual Meeting of Stockholders to Include Investor Presentation Open to All Interested Parties 14 Mar 2024 08:47:29
- Anixa Biosciences Announces Presentation at 24th Annual World Vaccine Congress 11 Mar 2024 08:02:28
- Anixa Biosciences Initiates Dosing in Second Cohort of Ovarian Cancer CAR-T Clinical Trial 12 Feb 2024 07:32:20
-
Anixa Biosciences Announces Participation in 2024 NeauxCancer Oncology Conference
29 Jan 2024 09:02:29
https://ir.anixa.com/press-releases/detail/1034/anixa-biosciences-announces-participation-in-2024
- Anixa Biosciences Announces Japanese Patent on Ovarian Cancer Vaccine Technology 23 Jan 2024 08:02:30
- Anixa Biosciences to Present at Biotech Showcase 2024 14 Dec 2023 15:34:28
- Anixa Biosciences Announces European Patent on Ovarian Cancer Vaccine Technology 27 Nov 2023 11:45:13
- Anixa Biosciences to Present at the Ovarian Cancer Research Alliance (OCRA) Ovarian Cancer National Conference 31 Oct 2023 09:15:09
-
Anixa Biosciences Announces Notice of Allowance of Additional Patent on Ovarian Cancer Vaccine Technology
27 Jul 2023 08:30:14
https://ir.anixa.com/press-releases/detail/1017/anixa-biosciences-announces-notice-of-allowance-of